Magnesium status and digoxin toxicity.

Br J Clin Pharmacol

Department of Clinical Biochemistry, Royal Victoria Hospital, Belfast.

Published: December 1991

AI Article Synopsis

  • A study involving 81 hospital patients on digoxin found that those with digoxin toxicity had impaired color vision and higher serum digoxin levels compared to those without toxicity.
  • Subjects with digoxin toxicity exhibited lower levels of serum and monocyte magnesium, while other electrolyte levels remained similar between the groups.
  • Magnesium deficiency was identified as a key factor contributing to digoxin toxicity, as it allowed toxicity to occur at lower serum digoxin concentrations.

Article Abstract

1. Eighty-one hospital patients receiving digoxin were separated into groups with and without digoxin toxicity using clinical criteria. Serum digoxin, sodium, potassium, calcium, creatinine, magnesium and monocyte magnesium concentrations were compared. 2. Subjects with digoxin toxicity had impaired colour vision (P less than 0.0001, Farnsworth-Munsell 100 hue test) and increased digoxin levels (1.89 (1.56-2.21) vs 1.34 (1.20-1.47) nmol l-1, P less than 0.01) (mean (95% confidence limits], though there was considerable overlap between two groups. 3. Subjects with digoxin toxicity had lower levels of serum magnesium (0.80 (0.76-0.84) vs 0.88 (0.85-0.91) mmol l-1, P less than 0.01) and monocyte magnesium (6.40 (5.65-7.16) vs 8.76 (7.81-9.71) mg g-1 DNA, P less than 0.01), but there were no significant differences in other biochemical parameters. A greater proportion of toxic subjects were receiving concomitant diuretic therapy (20/21 vs 37/60, P less than 0.05). 4. Magnesium deficiency was the most frequently identified significant electrolyte disturbance in relation to digoxin toxicity. In the presence of magnesium deficiency digoxin toxicity developed at relatively low serum digoxin concentrations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1368552PMC

Publication Analysis

Top Keywords

digoxin toxicity
24
digoxin
10
serum digoxin
8
monocyte magnesium
8
subjects digoxin
8
l-1 001
8
magnesium deficiency
8
magnesium
7
toxicity
6
magnesium status
4

Similar Publications

Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co-administered CYP3A substrates, potentially causing toxicity. Therefore, the prediction of drug-drug interactions (DDIs) and estimation of dosing requirements for concomitantly administered drugs is imperative.

View Article and Find Full Text PDF

Objective: The objective of this study was to satisfy the US FDA's Center for Devices and Radiological Health regarding the safety of targeted osmotic lysis (TOL), a novel treatment for advanced carcinomas, in Beagle dogs.

Methods: 12 intact Beagle dogs, 6 males and 6 females, were divided into 2 treatment groups of 6, each receiving 3 TOL cycles. For each 6-day cycle, digoxin was administered orally at 0.

View Article and Find Full Text PDF

Background: Digoxin is a commonly used cardiac glycoside drug in clinical practice, primarily transported by P-glycoprotein (P-gp) and susceptible to the influence of P-gp inhibitors/inducers. Concurrent administration of ritonavir and digoxin may significantly increase the plasma concentration of digoxin. Due to the narrow therapeutic window of digoxin, combined use may lead to severe toxic effects.

View Article and Find Full Text PDF

Investigation of drug-microbial interactions has gained prominence due to the increasing need to study pharmacomicrobiomics. Previous research has revealed the microbiome's role in drug metabolism, influencing efficacy, bioavailability, and toxicity. Several potential interactions have reported between drugs and microbes, including bioaccumulation, biotransformation, and the influence of drugs on microbial growth.

View Article and Find Full Text PDF
Article Synopsis
  • * Results indicated that certain tests, particularly cardiac biomarkers, blood gases, and specific drug levels, were perceived to pose a higher risk for patient harm due to erroneous results.
  • * There was strong agreement (91%) between medical biochemists and clinicians regarding the severity scores, highlighting the tests that require focused quality improvement efforts.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!